Palisade Bio, Inc. (PALI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
Palisade Bio, Inc. (PALI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .